Loading...

Immunomedics

Nasdaq:IMMU
Snowflake Description

High growth potential with excellent balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
IMMU
Nasdaq
$3B
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. The last earnings update was 98 days ago. More info.


Add to Portfolio Compare Print
  • Immunomedics has significant price volatility in the past 3 months.
IMMU Share Price and Events
7 Day Returns
-3.2%
NasdaqGM:IMMU
-0.8%
US Biotechs
0.5%
US Market
1 Year Returns
-10.6%
NasdaqGM:IMMU
-1.8%
US Biotechs
2%
US Market
IMMU Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Immunomedics (IMMU) -3.2% -18.3% -24.4% -10.6% 524.5% 183.7%
US Biotechs -0.8% 0.3% 5.7% -1.8% 14.9% 7.1%
US Market 0.5% 6.3% 1.9% 2% 45.1% 40.5%
1 Year Return vs Industry and Market
  • IMMU underperformed the Biotechs industry which returned -1.8% over the past year.
  • IMMU underperformed the Market in United States of America which returned 2% over the past year.
Price Volatility
IMMU
Industry
5yr Volatility vs Market
Related Companies

IMMU Value

 Is Immunomedics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Immunomedics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Immunomedics.

NasdaqGM:IMMU Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 6 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 13.2%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGM:IMMU
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 7.3%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.43
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.425 (1 + (1- 21%) (0.73%))
1.433
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.43
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.433 * 7.27%)
13.15%

Discounted Cash Flow Calculation for NasdaqGM:IMMU using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Immunomedics is arrived at by discounting future cash flows to their present value using the 2 stage method. We use analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGM:IMMU DCF 1st Stage: Next 5 year cash flow forecast
2019 2020 2021 2022 2023
Levered FCF (USD, Millions) -250.55 -344.05 -139.60 -65.20 202.70
Source Analyst x2 Analyst x2 Analyst x2 Analyst x2 Analyst x2
Present Value
Discounted (@ 13.15%)
-221.43 -268.73 -96.36 -39.78 109.29
Present value of next 5 years cash flows $-517.01
NasdaqGM:IMMU DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2023 × (1 + g) ÷ (Discount Rate – g)
= $202.70 × (1 + 2.73%) ÷ (13.15% – 2.73%)
$1,998.30
Present Value of Terminal Value = Terminal Value ÷ (1 + r)5
= $1,998.30 ÷ (1 + 13.15%)5
$1,077.40
NasdaqGM:IMMU Total Equity Value
Calculation Result
Total Equity Value = Present value of next 5 years cash flows + Terminal Value
= $-517.01 + $1,077.40
$560.39
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $560.39 / 190.37
$2.94
NasdaqGM:IMMU Discount to Share Price
Calculation Result
Value per share (USD) From above. $2.94
Current discount Discount to share price of $14.30
= -1 x ($14.30 - $2.94) / $2.94
-385.8%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Immunomedics is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Immunomedics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Immunomedics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:IMMU PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in USD $-1.29
NasdaqGM:IMMU Share Price ** NasdaqGM (2019-02-13) in USD $14.3
United States of America Biotechs Industry PE Ratio Median Figure of 32 Publicly-Listed Biotechs Companies 20.45x
United States of America Market PE Ratio Median Figure of 3,046 Publicly-Listed Companies 16.95x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Immunomedics.

NasdaqGM:IMMU PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:IMMU Share Price ÷ EPS (both in USD)

= 14.3 ÷ -1.29

-11.06x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Immunomedics is loss making, we can't compare its value to the US Biotechs industry average.
  • Immunomedics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Immunomedics's expected growth come at a high price?
Raw Data
NasdaqGM:IMMU PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -11.06x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
51.9%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 25 Publicly-Listed Biotechs Companies 1.91x
United States of America Market PEG Ratio Median Figure of 2,117 Publicly-Listed Companies 1.36x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Immunomedics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Immunomedics's assets?
Raw Data
NasdaqGM:IMMU PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in USD $1.84
NasdaqGM:IMMU Share Price * NasdaqGM (2019-02-13) in USD $14.3
United States of America Biotechs Industry PB Ratio Median Figure of 404 Publicly-Listed Biotechs Companies 3.03x
United States of America Market PB Ratio Median Figure of 5,122 Publicly-Listed Companies 1.81x
NasdaqGM:IMMU PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:IMMU Share Price ÷ Book Value per Share (both in USD)

= 14.3 ÷ 1.84

7.78x

* Primary Listing of Immunomedics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Immunomedics is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Immunomedics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Immunomedics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

IMMU Future Performance

 How is Immunomedics expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
51.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Immunomedics expected to grow at an attractive rate?
  • Immunomedics's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Immunomedics's earnings growth is expected to exceed the United States of America market average.
  • Immunomedics's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:IMMU Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:IMMU Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 51.9%
NasdaqGM:IMMU Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 62.3%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 19.8%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 14.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.4%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:IMMU Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:IMMU Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 1,388 696 1
2023-06-30 833 202 207 4
2022-12-31 835 328 1
2022-06-30 445 54 13 4
2021-12-31 314 -59 1
2021-06-30 170 25 -144 6
2020-12-31 48 -540 2
2020-06-30 43 -152 -305 5
2019-12-31 1 -265 1
2019-06-30 0 -155 -272 6
2018-12-31 1 1
NasdaqGM:IMMU Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-09-30 1 -163 -219
2018-06-30 2 -134 -274
2018-03-31 2 -110 -210
2017-12-31 3 -95 -234
2017-09-30 3 -66 -256
2017-06-30 3 -62 -153
2017-03-31 3 -61 -116
2016-12-31 3 -58 -71
2016-09-30 3 -52 -60
2016-06-30 3 -48 -59
2016-03-31 5 -45 -56
2015-12-31 5 -41 -53

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Immunomedics's earnings are expected to grow significantly at over 20% yearly.
  • Immunomedics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:IMMU Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Immunomedics Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:IMMU Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 2.79 2.79 2.79 1.00
2023-06-30 1.01 1.57 0.34 4.00
2022-12-31 1.38 1.38 1.38 1.00
2022-06-30 -0.18 -0.10 -0.25 2.00
2021-12-31 -0.28 -0.28 -0.28 1.00
2021-06-30 -0.66 -0.30 -0.90 4.00
2020-12-31 -1.79 -0.94 -2.64 2.00
2020-06-30 -1.41 -1.24 -1.68 4.00
2019-12-31 -1.34 -1.32 -1.35 2.00
2019-06-30 -1.42 -1.22 -1.69 5.00
2018-12-31 -1.56 -1.56 -1.56 1.00
NasdaqGM:IMMU Past Financials Data
Date (Data in USD Millions) EPS *
2018-09-30 -1.29
2018-06-30 -1.78
2018-03-31 -1.52
2017-12-31 -1.89
2017-09-30 -2.30
2017-06-30 -1.47
2017-03-31 -1.15
2016-12-31 -0.72
2016-09-30 -0.63
2016-06-30 -0.62
2016-03-31 -0.59
2015-12-31 -0.57

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Immunomedics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Immunomedics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Immunomedics has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

IMMU Past Performance

  How has Immunomedics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Immunomedics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Immunomedics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Immunomedics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Immunomedics's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Immunomedics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Immunomedics Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:IMMU Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 1.47 -219.26 57.36
2018-06-30 2.16 -273.84 43.31
2018-03-31 2.41 -210.06 26.54
2017-12-31 3.25 -233.82 28.13
2017-09-30 3.04 -255.75 27.05
2017-06-30 3.09 -153.21 23.08
2017-03-31 3.38 -115.85 16.52
2016-12-31 2.96 -70.54 7.54
2016-09-30 3.24 -59.84 6.63
2016-06-30 3.23 -59.04 7.59
2016-03-31 4.70 -55.54 7.68
2015-12-31 4.98 -53.30 7.70
2015-09-30 5.31 -50.99 7.69
2015-06-30 5.65 -48.00 9.87
2015-03-31 4.44 -47.45 10.48
2014-12-31 4.42 -45.20 11.08
2014-09-30 4.62 -42.64 11.51
2014-06-30 9.04 -35.43 9.41
2014-03-31 9.22 -31.26 8.74
2013-12-31 9.80 -13.15 8.02
2013-09-30 9.41 -9.44 7.45
2013-06-30 4.96 -11.38 6.98
2013-03-31 4.56 -10.65 6.81
2012-12-31 3.80 -26.52 6.68
2012-09-30 32.64 -0.66 6.71
2012-06-30 32.73 1.38 6.61
2012-03-31 42.89 10.61 7.68

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Immunomedics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Immunomedics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Immunomedics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Immunomedics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Immunomedics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

IMMU Health

 How is Immunomedics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Immunomedics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Immunomedics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Immunomedics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Immunomedics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 30x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Immunomedics Company Filings, last reported 4 months ago.

NasdaqGM:IMMU Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 339.32 19.80 585.54
2018-06-30 399.69 19.76 638.80
2018-03-31 71.82 201.94 358.79
2017-12-31 16.45 19.69 139.75
2017-09-30 -67.39 19.65 139.63
2017-06-30 -59.46 98.08 154.90
2017-03-31 -131.92 97.90 45.97
2016-12-31 -75.18 97.72 46.61
2016-09-30 -72.98 97.54 33.03
2016-06-30 -57.53 97.35 50.63
2016-03-31 -45.01 97.17 61.58
2015-12-31 -31.89 96.99 76.04
2015-09-30 -18.93 96.81 85.49
2015-06-30 -4.52 96.62 99.62
2015-03-31 4.76 96.44 106.19
2014-12-31 16.06 0.00 21.26
2014-09-30 26.71 0.00 31.99
2014-06-30 38.86 0.00 41.83
2014-03-31 20.05 0.00 20.93
2013-12-31 28.21 0.00 26.83
2013-09-30 35.81 0.00 34.73
2013-06-30 39.80 0.00 41.33
2013-03-31 43.53 0.00 47.80
2012-12-31 20.07 0.00 21.40
2012-09-30 24.78 0.00 25.52
2012-06-30 34.17 0.00 32.84
2012-03-31 38.78 0.00 39.05
  • Immunomedics's level of debt (5.8%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 5.8% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Immunomedics has sufficient cash runway for more than 3 years based on current free cash flow.
  • Immunomedics has sufficient cash runway for 2.4 years if free cash flow continues to grow at historical rates of 48.5% each year.
X
Financial health checks
We assess Immunomedics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Immunomedics has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

IMMU Dividends

 What is Immunomedics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Immunomedics dividends. Estimated to be 0% next year.
If you bought $2,000 of Immunomedics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Immunomedics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Immunomedics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:IMMU Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 21 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1997 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:IMMU Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2023-06-30
2022-12-31
2022-06-30
2021-12-31
2021-06-30 0.00 1.00
2020-12-31
2020-06-30 0.00 1.00
2019-12-31
2019-06-30 0.00 1.00
2018-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Immunomedics has not reported any payouts.
  • Unable to verify if Immunomedics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Immunomedics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Immunomedics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Immunomedics's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Immunomedics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Immunomedics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Immunomedics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

IMMU Management

 What is the CEO of Immunomedics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Michael Pehl
COMPENSATION $3,843,429
AGE 53
TENURE AS CEO 1.2 years
CEO Bio

Mr. Michael F. Pehl has been President and Chief Executive Officer at Immunomedics, Inc. since December 7, 2017. Mr. Pehl is a global pharmaceutical leader. Mr. Pehl served as Managing Director of Celgene GmbH. Mr. Pehl served as President of Hematology & Oncology at Celgene Corporation from March 2016 to August 21, 2017. Mr. Pehl served as Senior Vice President of Global Marketing at Celgene Corporation since July 2014. Mr. Pehl joined Celgene in 2006 as General Manager of Celgene Germany. He served as Head of Global Marketing, Head of Hematology Europe of Celgene in Germany. He served as Regional Vice President of Central Europe, Vice President, Head of Marketing Europe and Corporate Vice President. He spent 11 years at Celgene, Mr. Pehl has launched multiple blockbuster drugs in the areas of hematology and oncology, including Revlimid, Pomalyst and Abraxane. He spent 14 years at Amgen, Inc., holding various positions in oncology, rheumatology and nephrology in Germany and for Amgen Europe. Mr. Pehl has been Director at Immunomedics, Inc. since December 7, 2017. He has experience in hematology and oncology and has launched multiple blockbuster drugs in that space including Revlimid, Pomalyst, and Abraxane. Mr. Pehl received his Diploma in Molecular Biology and Biochemistry from Ludwig Maximilian University of Munich.

CEO Compensation
  • Insufficient data for Michael to compare compensation growth.
  • Michael's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Immunomedics management team in years:

0.8
Average Tenure
52
Average Age
  • The average tenure for the Immunomedics management team is less than 2 years, this suggests a new team.
Management Team

Michael Pehl

TITLE
President
COMPENSATION
$4M
AGE
53
TENURE
1.2 yrs

Morris Rosenberg

TITLE
Chief Technology Officer
COMPENSATION
$2M
AGE
58
TENURE
1.1 yrs

Brendan Delaney

TITLE
Chief Commercial Officer
COMPENSATION
$2M
AGE
43
TENURE
1.3 yrs

Rob Iannone

TITLE
Chief Medical Officer and Head of Research & Development
COMPENSATION
$3M
AGE
51
TENURE
0.8 yrs

Mike Garone

TITLE
Vice President of Finance
COMPENSATION
$542K
AGE
59

Usama Malik

TITLE
Chief Business Officer
AGE
44
TENURE
0.5 yrs

William Fricker

TITLE
Principal Accounting Officer
AGE
54
TENURE
0.5 yrs

Phyllis Parker

TITLE
Director of Administration

Chau Cheng

TITLE
Senior Director of Investor Relations & Corporate Secretary

Jared Freedberg

TITLE
General Counsel
AGE
50
TENURE
0.4 yrs
Board of Directors Tenure

Average tenure and age of the Immunomedics board of directors in years:

1.9
Average Tenure
57
Average Age
  • The average tenure for the Immunomedics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Behzad Aghazadeh

TITLE
Chairman
COMPENSATION
$319K
AGE
47

Michael Pehl

TITLE
President
COMPENSATION
$4M
AGE
53
TENURE
1.2 yrs

Scott Canute

TITLE
Director
COMPENSATION
$308K
AGE
57
TENURE
1.9 yrs

Peter Hutt

TITLE
Director
COMPENSATION
$295K
AGE
83
TENURE
1.9 yrs

Khalid Islam

TITLE
Director
COMPENSATION
$319K
AGE
63
TENURE
1.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
19. Jun 18 Buy venBio Select Advisor LLC Company 15. Jun 18 15. Jun 18 200,000 $23.39 $4,678,000
15. Jun 18 Buy venBio Select Advisor LLC Company 15. Jun 18 15. Jun 18 575,000 $24.00 $13,800,000
13. Mar 18 Sell David Goldenberg Individual 28. Feb 18 07. Mar 18 -97,729 $17.75 $-1,699,389
X
Management checks
We assess Immunomedics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Immunomedics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

IMMU News

Simply Wall St News

How Many Immunomedics, Inc. (NASDAQ:IMMU) Shares Do Institutions Own?

Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … We also tend to see lower insider ownership in companies that were previously publicly owned. … Our analysis of the ownership of the company, below, shows that

Simply Wall St -

How Financially Strong Is Immunomedics Inc (NASDAQ:IMMU)?

IMMU has sustained its debt level by about US$98.08M over the last 12 months made up of current and long term debt. … At this current level of debt, IMMU currently has US$154.90M remaining in cash and short-term investments , ready to deploy into the business. … Next Steps: At its current level of cash flow coverage, IMMU has room for improvement to better cushion for events which may require debt repayment.

Simply Wall St -

What Do Immunomedics Inc (NASDAQ:IMMU) Insiders Know That You Don't?

Immunomedics is one of United States’s large-cap stocks that saw some insider buying over the past three months, with insiders investing in more than 1 million shares during this period. … I will be analysing whether these buying activities are supported by favourable future outlook and recent share price volatility. … Next Steps: Immunomedics’s net buying tells us the stock is in favour with some insiders, coherent with the sizeable growth in expected earnings, in addition to the large share price movement around the same time.

Simply Wall St -

What Do Analysts Think About Immunomedics Inc's (IMMU) Earnings Trajectory?

The latest earnings release Immunomedics Inc's (NASDAQ:IMMU) announced in September 2017 signalled that losses became smaller relative to the prrior year's level - great news for investors Today I want to provide a brief commentary on how market analysts view Immunomedics's earnings growth outlook over the next few years and whether the future looks brighter. … NasdaqGM:IMMU Future Profit Dec 7th 17 Even though it is useful to be aware of the growth each year relative to today’s level, it may be more valuable to estimate the rate at which the earnings are growing every year, on average. … The slope of this line is the rate of earnings growth, which in this case is 55.78%.

Simply Wall St -

Is Now The Time To Bet On The Healthcare Sector And Immunomedics Inc (IMMU)?

Not surprisingly, this rate is more than double the growth rate of the US stock market as a whole. … However, if you’re relatively concentrated in biotech, you may want to value IMMU based on its cash flows to determine if it is overpriced based on its current growth outlook. … If IMMU has been on your watchlist for a while, now may be the time to enter into the stock, if you like its growth prospects and are not highly concentrated in the biotech industry.

Simply Wall St -

IMMU Company Info

Map
Description

Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140, a humanized antibody directed against an immune response target. Its other product candidates include products for the treatment of cancer and autoimmune diseases, including epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. Immunomedics, Inc. has clinical collaboration with AstraZeneca and MedImmune, to evaluate Imfinzi, a human monoclonal antibody against PD-L1, with sacituzumab govitecan as a frontline treatment of patients with TNBC and urothelial cancer; collaboration agreement with The Bayer Group for the development of epratuzumab; clinical and preclinical collaborations with academic cancer institutions, identifying new cancer indications for sacituzumab govitecan and the biology of the Trop-2 antigen; and research collaboration with the Memorial Sloan Kettering Cancer Center to investigate Sacituzumab Govitecan and Labetuzumab Govitecan in preclinical cancer models. Immunomedics, Inc. has a partnership agreement with the Samsung BioLogics Co., Ltd. to manufacture hRS7, an Immunomedics proprietary humanized antibody. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey.

Details
Name: Immunomedics, Inc.
IMMU
Exchange: NasdaqGM
Founded: 1982
$2,722,233,800
190,366,000
Website: http://www.immunomedics.com
Address: Immunomedics, Inc.
300 The American Road,
Morris Plains,
New Jersey, 07950,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM IMMU Common Stock Nasdaq Global Market US USD 11. Apr 1984
DB IM3 Common Stock Deutsche Boerse AG DE EUR 11. Apr 1984
LSE 0J9H Common Stock London Stock Exchange GB USD 11. Apr 1984
Number of employees
Current staff
Staff numbers
185
Immunomedics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/02/13 23:43
End of day share price update: 2019/02/13 00:00
Last estimates confirmation: 2019/02/12
Last earnings filing: 2018/11/07
Last earnings reported: 2018/09/30
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.